Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

799 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 in patients with hematologic malignancy.
Langerbeins P, Hallek M. Langerbeins P, et al. Among authors: hallek m. Blood. 2022 Jul 21;140(3):236-252. doi: 10.1182/blood.2021012251. Blood. 2022. PMID: 35544585 Free PMC article.
Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M, Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL Study Group (GCLLSG). Eichhorst BF, et al. Among authors: hallek m. Blood. 2011 Feb 10;117(6):1817-21. doi: 10.1182/blood-2010-04-282228. Epub 2010 Dec 7. Blood. 2011. PMID: 21139079 Free article.
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.
Reiners KS, Topolar D, Henke A, Simhadri VR, Kessler J, Sauer M, Bessler M, Hansen HP, Tawadros S, Herling M, Krönke M, Hallek M, Pogge von Strandmann E. Reiners KS, et al. Among authors: hallek m. Blood. 2013 May 2;121(18):3658-65. doi: 10.1182/blood-2013-01-476606. Epub 2013 Mar 18. Blood. 2013. PMID: 23509156 Free PMC article.
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
Cramer P, Fink AM, Busch R, Eichhorst B, Wendtner CM, Pflug N, Langerbeins P, Bahlo J, Goede V, Schubert F, Döhner H, Stilgenbauer S, Dreger P, Kneba M, Böttcher S, Mayer J, Hallek M, Fischer K. Cramer P, et al. Among authors: hallek m. Leuk Lymphoma. 2013 Aug;54(8):1821-2. doi: 10.3109/10428194.2013.796050. Epub 2013 Jun 12. Leuk Lymphoma. 2013. PMID: 23631654
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.
Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, Hurtz HJ, Stauch MB, Stilgenbauer S, Döhner H, Fink AM, Cramer P, Fischer K, Wendtner CM, Hallek M, Eichhorst B. Langerbeins P, et al. Among authors: hallek m. Am J Hematol. 2014 Dec;89(12):E239-43. doi: 10.1002/ajh.23841. Epub 2014 Sep 26. Am J Hematol. 2014. PMID: 25196783 Free article. Clinical Trial.
The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.
Langerbeins P, Bahlo J, Rhein C, Cramer P, Pflug N, Fischer K, Stilgenbauer S, Kreuzer KA, Wendtner CM, Eichhorst B, Hallek M. Langerbeins P, et al. Among authors: hallek m. Future Oncol. 2015;11(13):1895-903. doi: 10.2217/fon.15.95. Future Oncol. 2015. PMID: 26161926 Clinical Trial.
799 results